On Friday, Baird, a financial services firm, adjusted its price target for Elevance Health Inc. (NYSE: ELV), reducing it to $625 from the previous $649, while continuing to recommend the stock with an Outperform rating.
The firm identified transient near-term headwinds but suggested these present an attractive buying opportunity given the long-term prospects of the company.
The analyst from Baird noted that the incremental concerns over Medicaid utilization in the second half of the year are temporary. These headwinds are expected to be addressed as state rate adjustments are made to reflect actuarial soundness.
The firm believes these adjustments create a favorable buying opportunity for investors with a long-term view, as Elevance's fundamental thesis remains unchanged.
Looking ahead, Baird acknowledges potential risks related to political headlines as the year progresses, particularly those involving the Trump vs. Biden context. However, the firm anticipates that Elevance's valuation multiple has the potential to recover as the end of 2024 approaches, with increased visibility on Medicaid rates.
Baird also highlighted a slight revision in the company's long-term revenue growth compound annual growth rate (CAGR) for the period from 2022 to 2027. This adjustment is seen as a recalibration reflecting the past couple of years of Medicaid and Medicare Advantage experience, rather than indicative of any structural growth concerns for Elevance.
In other recent news, Elevance Health Inc. has been the subject of several significant developments. The company reported a strong Q2 performance with operating revenue of $43.22 billion and an adjusted EPS of $10.12, surpassing estimates.
Elevance also expanded its primary care services through a collaboration with the private equity firm Clayton, Dubilier & Rice.
RBC Capital upgraded its price target for Elevance's shares to $585, maintaining an Outperform rating, while BofA Securities downgraded the stock rating to Neutral due to Medicaid margin concerns. Truist Securities and TD Cowen reiterated a Buy rating, expressing confidence in the company's financial preparedness.
Morgan Stanley maintained an Overweight rating with a price target of $643, and Mizuho Securities raised Elevance's price target to $585, adjusting its adjusted earnings per share estimates for 2024 and 2025.
InvestingPro Insights
As Baird reiterates confidence in Elevance Health Inc.'s (NYSE: ELV) long-term potential, recent data from InvestingPro aligns with the firm's outlook. Elevance Health boasts a strong financial foundation, with a market capitalization of $117.04 billion and a robust revenue stream, having generated $171.72 billion over the last twelve months as of Q2 2024. This reflects a healthy revenue growth of 3.62% during the same period, underscoring the company's resilience in the face of transient challenges.
InvestingPro Tips highlight that Elevance Health is not just a prominent player in the Healthcare Providers & Services industry, but also a consistent performer with a history of raising its dividend for 13 consecutive years, indicative of a stable financial position. Additionally, the company's cash flows have proven sufficient to cover interest payments, which is a reassuring sign for investors looking at the company's debt management and dividend reliability. Moreover, analysts predict the company will remain profitable this year, having been profitable over the last twelve months.
For investors seeking in-depth analysis and more InvestingPro Tips, including insights on Elevance Health's low price volatility and management's share buyback strategy, visit Investing.com/pro/ELV. There are over 10 additional tips available to help refine your investment strategy. Remember, you can use coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.